CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)

Market Cap	291.64B
Revenue (ttm)	96.91B
Net Income (ttm)	-1.13B
Shares Out	147.22M
EPS (ttm)	-20.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	294,331
Average Volume	1,237,461
Open	1,967.00
Previous Close	1,981.00
Day's Range	1,967.00 - 2,005.00
52-Week Range	1,590.00 - 3,345.00
Beta	0.78
RSI	48.61
Earnings Date	Aug 13, 2025

About CMG Pharmaceutical

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 229
• Stock Exchange: KOSDAQ
• Ticker Symbol: 058820

Financial Performance

In 2024, CMG Pharmaceutical's revenue was 99.10 billion, an increase of 5.53% compared to the previous year's 93.91 billion. Earnings were 2.69 billion, a decrease of -58.26%.